Methods for Assessing Tophus Response During Urate Lowering Therapy in Treatment Tophaceous Gout
Systems and methods for assessment of the reduction of tophus burden with effective urate-lowering therapy were developed. The first application of computer-assisted methods for accessing tophus response included standardized digital photography, computer assisted measurement and analysis of tophi by an independent reader and blinded central reader paradigm. The ability of the method for computer-assisted analysis of digital photographs to quantify reduction in tophus size demonstrates its feasibility as a urate-lowering therapy monitoring tool in the treatment of tophaceous gout.
1 . A method for accessing and/or quantitating tophus response during a urate lowering therapy in a patient comprising:
a) obtaining a photograph of each baseline tophus before urate-lowering treatment and each tophus after said treatment;
b) measuring the longest dimension and the perpendicular dimension of said tophus before and after said treatment;
c) calculating the area of said tophus before and after said treatment by multiplying said longest dimension and said perpendicular dimension;
d) comparing the tophus area before and after said urate-lowering treatment; and
e) indicating that a change in tophus area from said baseline correlates with therapeutic efficacy.
2 . The method according to claim 1 wherein the urate-lowering therapy administered to a patient in need thereof is pegylated uricase therapy.
3 . The method according to claim 2 wherein pegylated uricase is administered at a dosage of 8 mg every 2 weeks.
4 . The method according to claim 2 , wherein pegylated uricase is administered at a dosage of 8 mg every 4 weeks.
5 . The method according to claim 2 , wherein the tophus photographs are taken after 25 weeks of pegylated uricase treatment.
6 . The method according to claim 2 , wherein the tophus photographs are taken after 19 weeks of pegylated uricase treatment.
7 . The method according to claim 2 , wherein the tophus photographs are taken after 13 weeks of pegylated uricase treatment.
8 . The method according to claim 1 wherein said patient is suffering from gout.
9 . The method according to claim 9 wherein said gout is refractory to conventional therapy.
10 . The method according to claim 9 wherein said gout is chronic or tophaceous.
11 . The method according to claim 2 wherein at least 75% decrease in the tophus area from baseline correlates with marked response to pegylated uricase therapy
12 . The method according to claim 2 wherein 100% decrease in the tophus area from baseline correlates with complete response to pegylated uricase therapy.
13 . The method according to claim 2 wherein at least 75% decrease in the tophus area from baseline correlates with marked response to pegylated uricase therapy
14 . The method according to claim 2 wherein at least 50% decrease in the tophus area from baseline correlates with partial response to pegylated uricase therapy.
15 . The method according to claim 2 wherein at least 25% increase in the tophus area from baseline correlates with progressive disease.
16 . The method according to claim 1 wherein the tophus is characterized as measurable.
17 . The method according to claim 1 wherein the tophus is characterized as unmeasured.